Is DGX a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Organic volume growth, with revenue (ttm) at ~$11.5B. The bear case rests on the largest risk is reimbursement policy: Medicare rates under PAMA face potential cuts (a delay pushed reductions toward 2027, but a roughly 15 percent cut to hundreds of tests looms without permanent reform), and private-payer pricing pressure caps growth. Analysts covering it are spread from $204.00 to $265.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The largest risk is reimbursement policy: Medicare rates under PAMA face potential cuts (a delay pushed reductions toward 2027, but a roughly 15 percent cut to hundreds of tests looms without permanent reform), and private-payer pricing pressure caps growth. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $204.00, -13.5% from the $235.80 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Organic volume growth. Requisition volumes grew roughly 11 percent year over year in Q1 2026, with organic volume up about 10.8 percent. The most optimistic analyst target on DGX is $265.00, +12.4% from the $235.80 price. That figure is only reachable if this thesis works close to its best case.

The largest risk is reimbursement policy: Medicare rates under PAMA face potential cuts (a delay pushed reductions toward 2027, but a roughly 15 percent cut to hundreds of tests looms without permanent reform), and private-payer pricing pressure caps growth. Labor shortages in clinical lab technologists and molecular specialists can raise costs and constrain capacity. Increased FDA oversight of laboratory-developed tests could add compliance burden. Acquisition-led growth carries integration and overpayment risk, and a large debt load from deal activity adds interest expense. Finally, the business is competitive and partly commoditized, so share losses to Labcorp, hospital in-sourcing, or specialty labs would pressure both volume and margin. The most pessimistic published target is $204.00, -13.5% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Quest Diagnostics operates one of the largest clinical laboratory networks in the United States, processing billions of test results a year across a footprint of patient service ce

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Organic volume growth) stalling in the reported numbers rather than in the narrative, the risk above (the largest risk is reimbursement policy: Medicare rates under PAMA face potential cuts (a delay pushed reductions toward 2027, but a roughly 15 percent cut to hundreds of tests looms without permanent reform), and private-payer pricing pressure caps growth) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Quest Diagnostics is one of the largest US clinical laboratory operators. It performs diagnostic testing (from routine blood and metabolic panels to advanced molecular and genomic tests) for physicians, hospitals, employers, health plans, and consumers across a national network of labs and patient service centers.

Yes. As of July 2026 Quest Diagnostics has a market capitalization around $22.8 billion and trailing-twelve-month revenue near $11.5 billion, making it a large-cap company and one of the two leaders in the US independent lab market alongside Labcorp.

In Q1 2026 revenue rose about 9.2 percent year over year with requisition volume up roughly 11 percent. Full-year 2026 guidance implies revenue growth of about 6.8 to 7.8 percent, driven by organic volume, acquisitions, and advanced diagnostics rather than price increases.